Grygiel Nancy A.

SEC source: 0000318154-26-000129 · form4.xml · derivative · entry 7

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,948

Underlying: Common Stock · 1,000 shares

Expires 2029-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000129 · form4.xml · derivative · entry 6

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,970 shares

Expires 2028-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000129 · form4.xml · nonDerivative · entry 4

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,340

F1 · shares: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

F2 · balance_after: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000129 · form4.xml · nonDerivative · entry 3

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,340

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000129 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,340

F1 · shares: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

SEC source: 0000318154-26-000129 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,310

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000088 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,330

F1 · balance_after: These shares include 58 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000076 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,418

F2 · balance_after: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000076 · form4.xml · derivative · entry 4

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,334

Underlying: Common Stock · 3,167 shares

Expires 2036-05-05

F3 · derivative.exercise_date: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.

SEC source: 0000318154-26-000076 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,494

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

SEC source: 0000318154-26-000064 · form4.xml · nonDerivative · entry 3

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,009

F1 · price: The price reported is an average price of $323.7272 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer

F2 · balance_after: These shares include 72 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000064 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,246

SEC source: 0000318154-26-000064 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,362

SEC source: 0000318154-26-000029 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,488

F1 · balance_after: These shares include 122 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000018 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,249

F1 · balance_after: These shares include 110 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000083 · form4.xml · derivative · entry 7

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,639 shares

Expires 2027-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-25-000083 · form4.xml · derivative · entry 6

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,970

Underlying: Common Stock · 1,500 shares

Expires 2028-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-25-000083 · form4.xml · nonDerivative · entry 4

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,225

F1 · price: The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000083 · form4.xml · nonDerivative · entry 3

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,864

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-25-000083 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,225

F1 · price: The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

SEC source: 0000318154-25-000083 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-25-000062 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,209

F1 · balance_after: These shares include 80 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-013783 · form4.xml · derivative · entry 3

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,824

Underlying: Common Stock · 3,824 shares

Expires 2035-05-06

F4 · derivative.exercise_date: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/6/2026.

SEC source: 0001127602-25-013783 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,463

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/6/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 67 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-013530 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,872

F1 · balance_after: These shares include 67 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-013530 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,983

SEC source: 0001127602-25-013283 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,101

F1 · balance_after: These shares include 101 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-010057 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,214

F1 · balance_after: These shares include 128 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-008425 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,713

F1 · balance_after: These shares include 114 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-003500 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,210

F1 · balance_after: These shares include 114 Dividend Equivalents (DEs) granted pursuant to the Company's Equity Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-021277 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,771

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Plan): 199 RSUs which will vest on 4/30/2025; 435 RSUs which will vest in installments of 214 on 5/2/2025, and one installment of 221 on 5/2/2026; 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027; and 499 RSUs which will vest in installments of 164 on 5/7/2026, 165 on 5/7/2027, and 170 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 86 Dividend Equivalents (DEs) granted pursuant to the Company's Equity Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-014855 · form4.xml · derivative · entry 3

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,244

Underlying: Common Stock · 3,244 shares

Expires 2034-05-07

F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.

SEC source: 0001127602-24-014855 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,300

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,780 RSUs which will vest on 7/31/2024; 199 RSUs which will vest on 4/30/2025; 435 RSUs which will vest in installments of 214 on 5/2/2025, and one installment of 221 on 5/2/2026; 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027; and 499 RSUs which will vest in installments of 164 on 5/7/2026, 165 on 5/7/2027, and 170 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 424 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-014509 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,801

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,780 RSUs which will vest on 7/31/2024; 199 RSUs which will vest on 4/30/2025; 435 RSUs which will vest in installments of 214 on 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 424 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-014198 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,883

F1 · price: The price reported is an average price. The prices ranged from $313.071 to $313.0923 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 199 RSUs which will vest on 4/30/2025; 435 RSUs which will vest in installments of 214 on 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 443 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-014194 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 199 RSUs which will vest on 4/30/2025; 435 RSUs which will vest in installments of 214 on 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 443 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-013815 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,114

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 199 RSUs which will vest on 4/30/2025; 649 RSUs which will vest in two installments of 214 each on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 457 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-010854 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,220

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plan: 154 RSUs which will vest on 5/3/2023; 284 RSUs which will vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 476 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-009244 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,866

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 649 RSUs which will vest in two installments of 214 each on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 435 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-028779 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,874

F1 · price: The price reported is an average price. The prices ranged from $273.00 to $273.17 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 649 RSUs which will vest in two installments of 214 each on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 397 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-026976 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,970

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 649 RSUs which will vest in two installments of 214 each on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 397 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-021594 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,095

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 304 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015047 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,224

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 571 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-014614 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,278

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 284 RSUs which will vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 584 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-014614 · form4.xml · derivative · entry 4

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,375

Underlying: Common Stock · 5,375 shares

Expires 2033-05-02

F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.

SEC source: 0001127602-23-014614 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,340

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.

SEC source: 0001127602-23-014153 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,705

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plan: 154 RSUs which vest in one installment on 5/3/2023; 284 RSUs which vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 392 RSUs which vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 604 DEs granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-010917 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,778

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plan: 154 RSUs which will vest on 5/3/2023; 284 RSUs which will vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 616 DEs granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-009500 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,032

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plan: 154 RSUs which will vest on 5/3/2023; 284 RSUs which will vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 540 DEs granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-025154 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,009

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plan: 154 RSUs which will vest on 5/3/2023; 284 RSUs which will vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 7/31/2023 and 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 485 DEs granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.